CalciMedica Inc CALC

Healthcare Biotechnology

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.

NDAQ:CALC - Post by User

CalciMedica Inc

<< Previous

Bullboard Posts

Next >>

(169)
•••

Post by yukon_goldon Mar 09, 2023 8:43pm

557 Views

Post# 35329622

Graycliff Exploration CEO Update: WATCH AND READ

CEO Update:

Progress at Shakespeare and Baldwin and New Lunge Acquisition

We thought we were due for an update, so we recorded CEO James Macintosh talking about Graycliff's project portfolio, past milestones and upcoming catalysts, and then we did the written version so you can pick and choose -- or watch and read both.